A Maryland bill would start investigations and impose fines to stop generic drug companies from increasing their prices exorbitantly.
The bill (H.B. 631) would prohibit a manufacturer from engaging in “price gouging” in the sale of an “essential off-patent or generic drug.” Specifically, it would empower the Maryland attorney general to sue a generic manufacturer that institutes unjustified price increases.
“The bill would grant the Attorney General considerable discretion in pursuing so-called and poorly defined ‘price gouging,’” Stephanie Trunk, a health-care attorney with Arent Fox LLP in Washington, told me. If the attorney general believes the price increase isn’t justified, he or she can pursue a case against the manufacturer for price gouging. The bill also would impose a civil penalty of up to $10,000 for each violation.
But the Association for Accessible Medicines (AAM), formerly the Generic Pharmaceutical Association, said in a position paper that the bill “ignores the real cause of increasing prescription drug costs” because it “only applies to generic drugs, not much expensive brand-name and specialty drugs that cost Maryland patients and tax-payers billions of dollars per year.”
The AAM said brand name and specialty drugs cost Maryland patients over $3.5 billion, while generics saved Maryland $3.7 billion in just one year alone.
The bill’s standards on when a price increase is “unjustified” are vague, the AAM said. “Given the vague standards set forth in the bill, companies would perpetually be at risk of facing prosecution for taking actions that normally occur during the course of business within the competitive free market.”
The bill, introduced in January, has more than 80 sponsors, including Democrats and Republicans. The Maryland House of Delegates passed the bill on March 20. A date hasn’t been set yet for the Maryland Senate to vote on the bill.
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)